Dernières nouvelles pour DexCom (NASDAQ:DXCM) Stock

DexCom

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

DexCom Inc

DEXCOM ORD

Billionaire investor Chase Coleman's hedge fund, Tiger Global Management, filed its latest <a href="https://www.sec.gov/Archives/edgar/data/1167483/000091957424006690/xslForm13F_X02/infotable.xml">Form 13F</a> on Thursday and disclosed its trading activity from the prior quarter. Here's a look at Tiger Global's <a href="https://www.benzinga.com/opinion/24/08/40422936/steal-these-two-stock-ideas-from-the-best-investors-in-the-world">portfolio changes.&nbsp;</a>
The Details: Tiger Global has $23.439 billion in assets under management and made no changes to its top five holdings:&nbsp;
<ul>
<li>Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) </li>
<li>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) </li>
<li>Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) </li>
<li>Apollo Global Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) </li>
<li>Sea Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) </li>
</ul>
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a>
New Positions: Tiger Global opened three new positions including a $801.3 million stake in Flutter Entertainment Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>), the parent company of FanDuel. The fund also opened a $201.4 million position in Sherwin-Williams Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) and a $48.9 million position in South Korean e-commerce platform Coupang, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>). 
Notable Trades: Tiger Global added 564,090 shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) to its portfolio, bringing its total number of shares owned to 3,634,980. The fund also increased its stake in Take-Two Interactive Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) by 195,714 shares, bringing its current holdings to 5,839,256 shares valued at $897.5 million. 
Closed Positions: The hedge fund closed out its positions in Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) and DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Image created using artificial intelligence via MidJourney.

News

Hedge Funds

Movers

ALAB

CPNG

DXCM

FLUT

GOOGL

MSFT

TTWO

Tiger Global Hedge Fund Buys Flutter Entertainment Stock, Sells DexCom

In the latest quarter, 12 analysts provided ratings for DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated DexCom and provided 12-month price targets. The average target is $97.67, accompanied by a high estimate of $120.00 and a low estimate of $82.00. Observing a downward trend, the current average is 2.74% lower than the prior average price target of $100.42. 
<img src="https://www.benzinga.com/files/images/story/2024/1729882856_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of DexCom among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$99.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mike Kratky</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$87.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$82.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$113.00</td>
<td>$138.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to DexCom. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of DexCom compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for DexCom's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into DexCom's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DXCM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DexCom analyst ratings.</a>
<h2>Delving into DexCom's Background</h2>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>Breaking Down DexCom's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: DexCom displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 15.26%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: DexCom's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 14.29%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.13%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): DexCom's ROA excels beyond industry benchmarks, reaching 2.16%. This signifies efficient management of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 1.07, DexCom faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Expectations For DexCom's Future

DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) reported better-than-expected third-quarter <a href="https://www.benzinga.com/news/earnings/24/10/41532118/dexcom-stock-drops-after-q3-results-announces-c-suite-transition#:~:text=The%20Details%3A%20DexCom%20reported%20quarterly,the%20same%20period%20last%20year.">results on Thursday</a>. 
DexCom reported quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents. Quarterly revenue came in at $994.2 million which beat the analyst consensus estimate of $990.71 million and is an increase over sales of $975 million from the same period last year.
DexCom also announced Teri Lawver, executive vice president and chief commercial officer, will retire at the end of the year. Lawver will continue as a special advisor to Dexcom through early 2025 and Kevin Sayer, chairman, president and CEO, will assume leadership of the commercial organization as the company conducts a global search for a new chief commercial officer.
DexCom shares fell 1.6% to trade at $73.68 on Friday.
These analysts made changes to their price targets on DexCom following earnings announcement.
<ul>
<li>Wells Fargo analyst Larry Biegelsen maintained DexCom with an Overweight and raised the price target from $80 to $90.</li>
<li>Leerink Partners analyst Mike Kratky maintained DexCom with an Outperform and lowered the price target from $90 to $87.</li>
<li>JP Morgan analyst Robbie Marcus maintained the stock with a Neutral and raised the price target from $75 to $85.</li>
<li>Oppenheimer analyst Steven Lichtman maintained DexCom with an Outperform and lowered the price target from $115 to $105.</li>
<li>RBC Capital analyst Shagun Singh maintained the stock with an Outperform and lowered the price target from $120 to $115.</li>
<li>Bernstein analyst Lee Hambright maintained DexCom with an Outperform and raised the price target from $82 to $86.</li>
<li>Raymond James analyst Jayson Bedford maintained DexCom with a Strong Buy and lowered the price target from $115 to $99.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41543872/how-to-earn-500-a-month-from-waste-management-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Waste Management Stock Ahead Of Q3 Earnings</a></li>
</ul>

Earnings

Price Target

Trading Ideas

These Analysts Revise Their Forecasts On DexCom Following Q3 Results

Bernstein analyst Lee Hambright maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Outperform and raises the price target from $82 to $86.

Bernstein Maintains Outperform on DexCom, Raises Price Target to $86

Raymond James analyst Jayson Bedford maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Strong Buy and lowers the price target from $115 to $99.

Raymond James Maintains Strong Buy on DexCom, Lowers Price Target to $99

Stocks are ending the week on a high note, with tech leading the charge as investors position ahead of next week&#8217;s pivotal earnings releases from <a href="https://www.benzinga.com/topic/magnificent-7">five of the &#8220;Magnificent Seven&#8221; stocks.</a>
Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) will all report quarterly earnings between Oct. 29 and Oct. 31.
Combined, nearly 45% of the S&amp;P 500 by market cap is set to report results next week, with other heavyweights including McDonald&#8217;s Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>), Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Mastercard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) and Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>).
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) continued its upward trajectory on Friday, rising 2.7% following a massive 21% jump on Thursday — its biggest one-day gain since May 2013.
The S&amp;P 500 was up 0.5% at midday trading in New York, while the Nasdaq 100 surged by 1.5%, fueled by semiconductor stocks. 
The Dow Jones Industrial Average fell 0.3%, on track to end a six-week winning streak. The U.S. dollar strengthened further, with the DXY Index rising past the 104 mark, setting up for a fourth straight week of gains. Meanwhile, Treasury yields were steady. 
WTI crude rose 1.8%, driven by concerns over geopolitical tensions in the Middle East. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is up slightly at $67,695.
<h1 class="wp-block-heading">Friday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % change</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,500.56</td>
<td>1.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,839.28</td>
<td>0.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,219.60</td>
<td>0.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,271.11</td>
<td>-0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:50 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent102225&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.5% to $582.19.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;eased 0.2% to $423.18.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rallied 1.3% to $498.83.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.2% up to $220.09.</li>
<li>The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up by 1.4%. The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 0.9%.</li>
</ul>
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
<ul>
<li>Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) rallied 7% to levels last seen in October 2021 on better-than-expected quarterly results. </li>
<li>Digital Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) rallied over 10% after reporting record new lease bookings. </li>
</ul>
Other stocks reacting to earnings included:
<ul>
<li>Ameriprise Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>), down 0.13%</li>
<li>DexCom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), down 1%</li>
<li>ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) up 7.6%, </li>
<li>Skechers U.S.A. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) down 0.2%, </li>
<li>Western Digital Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) up 7.6%, </li>
<li>Deckers Outdoor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>), up 11%</li>
<li>Edward Lifesciences Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), down by 0.6%</li>
<li>HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), down 10%, </li>
<li>Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>), up 6%, </li>
<li>Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>), down 3.4%, </li>
<li>Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), up 6.7%, </li>
<li>Saia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>), up 9.2%. </li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41549147/goldman-sachs-analyst-remains-bullish-on-boeing-despite-weak-q3-long-term-deep-valu">Goldman Sachs Analyst Remains Bullish On Boeing Despite Weak Q3: &#8216;Long-Term Deep-Value Opportunity</a>&#8216;</li>
</ul>
Photo: Shutterstock

Equities

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

$BTC

AAPL

AMZN

DECK

SPDR Dow Jones Industrial Average ETF Trust

GOOG

RIVN

SAIA

TSLA

Select Sector SPDR-Consumer Discretionary

Tech Stocks Rally As Investors Await Magnificent 7 Earnings; Dollar Eyes Fourth Straight Positive Week: What's Driving Markets Friday?

RBC Capital analyst Shagun Singh maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Outperform and lowers the price target from $120 to $115.

RBC Capital Maintains Outperform on DexCom, Lowers Price Target to $115

<a href="https://www.bloomberg.com/news/articles/2024-10-25/apple-secretly-tests-blood-sugar-app-in-sign-of-health-ambitions" title="https://www.bloomberg.com/news/articles/2024-10-25/apple-secretly-tests-blood-sugar-app-in-sign-of-health-ambitions">https://www.bloomberg.com/news/articles/2024-10-25/apple-secretly-tests-blood-sugar-app-in-sign-of-health-ambitions</a>

PODD

'Apple Staff Tests Blood-Sugar App In Sign Of Health Ambitions' - Bloomberg News

Oppenheimer analyst Steven Lichtman maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Outperform and lowers the price target from $115 to $105.

Oppenheimer Maintains Outperform on DexCom, Lowers Price Target to $105

JP Morgan analyst Robbie Marcus maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Neutral and raises the price target from $75 to $85.

JP Morgan Maintains Neutral on DexCom, Raises Price Target to $85

Leerink Partners analyst Mike Kratky maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Outperform and lowers the price target from $90 to $87.

Leerink Partners Maintains Outperform on DexCom, Lowers Price Target to $87

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Friday.
Shares of Capri Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) fell sharply in today's pre-market trading following reports that a judge has blocked the company's<a href="https://www.benzinga.com/m-a/24/10/41533172/capri-holdings-stock-drops-by-half-after-judge-blocks-tapestry-merger"> pending merger with Tapestry.</a>
Following an eight-day trial in which the U.S. Federal Trade Commission argued that a merger between Capri and Tapestry would remove competition from the U.S. handbag space, a U.S. judge has moved to block the pending merger, according to Reuters.
Capri shares tumbled 47.1% to $22.01 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Coursera, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) shares dipped 19.2% to $6.16 in today's pre-market trading after the company issued fourth-quarter revenue guidance below estimates and cut its FY24 revenue guidance,</li>
<li>The Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBBK#NASDAQ">TBBK</a>) shares declined 15.4% to $46.51 following downbeat quarterly results.</li>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) dipped 8.1% to $5.55 in pre-market trading as the company announced the pricing of public offering of common stock.</li>
<li>Tevogen Bio Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares fell 7.8% to $2.36 in pre-market trading. Tevogen Bio recently announced its Artificial Intelligence effort, Tevogen AI, has joined Microsoft for Startups.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) shares fell 6.6% to $69.89 in pre-market trading following third-quarter results.</li>
<li>Sibanye Stillwater Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBSW#NYSE">SBSW</a>) declined 4.6% to $4.73 in pre-market trading after surging more than 12% on Thursday.</li>
<li>The Boston Beer Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) shares fell 4% to $289.80 in pre-market trading following third-quarter results.</li>
<li>Masimo Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) shares fell 4% to $135.23 in pre-market trading. Masimo will report third quarter financial results, after the closing bell on Tuesday, Nov. 5.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41528323/jim-cramer-says-hold-on-to-palantir-let-them-walk-it-up-warns-that-travere-therapeutics-is-losing-a">Jim Cramer Says &#8216;Hold On&#8217; To Palantir, &#8216;Let Them Walk It Up&#8217;; Warns That Travere Therapeutics Is Losing A &#8216;Ton Of Money&#8217;</a></li>
</ul>

Pre-Market Outlook

Markets

COUR

CPRI

JOBY

MASI

SBSW

TBBK

TVGN

Capri, Coursera, DexCom And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Wells Fargo analyst Larry Biegelsen maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Overweight and raises the price target from $80 to $90.

Wells Fargo Maintains Overweight on DexCom, Raises Price Target to $90

WIIM

DexCom shares are trading lower. The company reported Q3 financial results.

DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) reported its third-quarter results after Thursday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/10/b41529639/dexcom-reports-third-quarter-2024-financial-results">details from the report.  </a>
The Details: DexCom reported quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents. Quarterly revenue came in at $994.2 million which beat the analyst consensus estimate of $990.71 million and is an increase over sales of $975 million from the same period last year.
DexCom also announced Teri Lawver, executive vice president and chief commercial officer, will retire at the end of the year. Lawver will continue as a special advisor to Dexcom through early 2025 and Kevin Sayer, chairman, president and CEO, will assume leadership of the commercial organization as the company conducts a global search for a new chief commercial officer.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41524809/boeing-strike-drags-on-union-contract-rejection-adds-further-uncertainty-costs-reco">Boeing Strike Drags On: Union Contract Rejection &#8216;Adds Further Uncertainty, Costs, Recovery Delays,&#8217; Says Analyst</a>
Dexcom&#8217;s third-quarter results were in line with our expectations as our team responded quickly to the business dynamics that emerged earlier this year,&#8221; said Sayer. &#8220;We made significant progress over the quarter to drive improved execution, leaving the company on track to continue on our momentum in the fourth quarter and into 2025.&#8221;
Outlook: DexCom affirmed its fiscal 2024 sales outlook of between $4 billion and $4.05 billion.
DXCM Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, DexCom shares are down 7.94% after-hours at $68.91 at the time of publication Thursday.
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41489239/bank-of-america-ceo-cautions-fed-not-to-go-too-fast-or-too-slow-on-interest-rate-cuts">Bank Of America CEO Cautions Fed Not To &#8216;Go Too Fast Or Too Slow&#8217; On Interest Rate Cuts</a></li>
</ul>
Photo: Shutterstock

Management

After-Hours Center

DexCom Stock Drops After Q3 Results, Announces C-Suite Transition

<h3>Gainers</h3>
<ul>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares rose 48.3% to $0.53 during Thursday's after-market session. The market value of their outstanding shares is at $7.0 million. </li>
<li>Lyell Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYEL#NASDAQ">LYEL</a>) stock moved upwards by 32.92% to $1.45. The company's market cap stands at $370.9 million. </li>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) shares rose 9.64% to $1.25. The market value of their outstanding shares is at $41.3 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares increased by 8.74% to $0.87. The company's market cap stands at $20.7 million. </li>
<li>Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) shares increased by 7.32% to $75.5. The market value of their outstanding shares is at $45.4 billion. As per the press release, Q3 earnings came out today. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock increased by 6.85% to $1.87. The market value of their outstanding shares is at $21.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) stock declined by 15.2% to $63.5 during Thursday's after-market session. The company's market cap stands at $25.4 billion. The company's, Q3 earnings came out today. </li>
<li>Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) stock declined by 14.29% to $1.02. The market value of their outstanding shares is at $44.1 million. </li>
<li>Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) shares declined by 10.98% to $200.0. The company's market cap stands at $13.3 billion. As per the press release, Q3 earnings came out today. </li>
<li>Allakos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) stock decreased by 6.65% to $1.11. The market value of their outstanding shares is at $98.7 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock fell 6.34% to $0.82. The market value of their outstanding shares is at $2.2 million. </li>
<li>Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) shares fell 5.55% to $0.71. The market value of their outstanding shares is at $2.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLK

BNOX

LYEL

ONMD

QNCX

RVPH

SCPX

VTAK

12 Health Care Stocks Moving In Thursday's After-Market Session

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) affirms FY2024 sales outlook from $4.00 billion-4.05 billion to $4.00 billion-4.05 billion.

Guidance

DexCom Affirms FY2024 Sales Guidance from $4.00B-4.05B to $4.00B-4.05B (Est $4.013B)

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.43 by 4.65 percent. The company reported quarterly sales of $994.20 million which beat the analyst consensus estimate of $990.71 million by 0.35 percent. This is a 1.97 percent increase over sales of $975.00 million the same period last year.

Earnings Beats

DexCom Q3 2024 Adj EPS $0.45 Beats $0.43 Estimate, Sales $994.20M Beat $990.71M Estimate

Financial giants have made a conspicuous bearish move on DexCom. Our analysis of options history for DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) revealed 33 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 54% showed bearish tendencies. Out of all the trades we spotted, 11 were puts, with a value of $858,857, and 22 were calls, valued at $1,105,260.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $65.0 to $100.0 for DexCom during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for DexCom's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of DexCom's whale trades within a strike price range from $65.0 to $100.0 in the last 30 days. 
<h3>DexCom Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729795525_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$10.2</td>
<td>$9.6</td>
<td>$9.9</td>
<td>$65.00</td>
<td>$297.0K</td>
<td>155</td>
<td style="text-align: right;">300</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$28.0</td>
<td>$27.8</td>
<td>$28.0</td>
<td>$100.00</td>
<td>$162.4K</td>
<td>1.0K</td>
<td style="text-align: right;">58</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/01/24</td>
<td>$4.9</td>
<td>$4.7</td>
<td>$4.7</td>
<td>$74.00</td>
<td>$109.0K</td>
<td>996</td>
<td style="text-align: right;">480</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$14.0</td>
<td>$13.5</td>
<td>$13.5</td>
<td>$85.00</td>
<td>$108.0K</td>
<td>53</td>
<td style="text-align: right;">80</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$18.9</td>
<td>$18.8</td>
<td>$18.8</td>
<td>$85.00</td>
<td>$81.2K</td>
<td>0</td>
<td style="text-align: right;">44</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
After a thorough review of the options trading surrounding DexCom, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is DexCom Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 3,281,825, the DXCM's price is up by 2.46%, now at $74.26. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 0 days.</li>
</ul>
<h3>Professional Analyst Ratings for DexCom</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $120.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on DexCom with a target price of $120. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for DexCom with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

A Closer Look at DexCom's Options Market Dynamics

In a report released yesterday, Robbie Marcus from J.P. Morgan maintained a Hold rating on Dexcom (DXCM – Research Report), with a price target of ...

J.P. Morgan Sticks to Its Hold Rating for Dexcom (DXCM)

The Ithaka Group Q3 2024 Commentary

Stocks with cheap implied volatility – JPM

Baron WealthBuilder Fund Q3 2024 Shareholder Letter

Tracking Baillie Gifford's 13F Portfolio - Q3 2024 Update

Wells Fargo's Growth List – META, CPAY, DXCM, and more

Aristotle Large Cap Growth Q3 2024 Commentary

Baird Q3 2024 Mid Cap Growth Equity Fund Commentary

Tiger Global's top Q3 trades include DexCom exit, new stake in Sherwin-Williams

Chase Coleman's Tiger Global disclosed in an SEC filing its holdings as of September 30, 2024. Tiger's three new buys during the third quarter incl...

Tiger Global take new stake in Flutter, cuts stake in Uber

AAON

ABNB

ACGL

ACGLN

ACGLO

ADPT

ALGN

ALLY

ALNY

AMAT

APTV

ASML

ASMLF

AVGO

BCAP

BMRN

BROE

BROS

BURL

BWXT

CASY

COIN

CPAY

CRWD

CSGP

DASH

DLTR

EPAM

ESTC

EXPE

FANG

FIVE

GWRE

ICLR

IDXX

ILMN

INTC

ISRG

KEYS

KLAC

KNSL

LRCX

LSCC

MANH

MELI

MKTX

MPWR

MRNA

MSCI

NFLX

NVDA

ORLY

PARA

PAYC

PCAR

PLNT

PLTR

POOL

RACE

RGEN

RYAAY

RYAOF

SBAC

SBUX

SCHW

SHOP

SNOW

SNPS

SPOT

STNE

TECH

TREX

UBER

VEEV

WDAY

Screenshot 2024-10-03 at 5.30.47 PM

Health Care

General

GCTK

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Screenshot 2024-08-23 at 5.43.44 PM

Biotech

Poster Presentations, Upcoming Human Trials, Recently Secured Funding And More: Glucotrack&#39;s Plans To Transform The Continuous Glucose Monitoring Market

Movers & Shakers

Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes – Glucotrack Wants To Make It Easier

Press Releases

DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit

Legal

DXCM Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc.  (DXCM) Investors of Filing Deadline in Class Action Lawsuit

Comments

DexCom

Actualités

Dernières nouvelles pour DexCom (NASDAQ:DXCM) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL